A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

One in four people are left to cope alone after a diagnosis with dementia, research has found. The study by The Alzheimer’s ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving landscape of Alzheimer's treatments.

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...